Press releases

Oxford BioMedica Interim Management Statement November 2012

Oxford, UK 14 November 2012: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 July to 13 November 2012.

First patient treated in Phase II study for TroVax® in colorectal cancer led by Cardiff University, Wales (UK)

Initial data trends from US Phase II trial in hormone refractory prostate cancer (HRPC) indicate that the Company’s pre-treatment biomarker can identify patients most likely to benefit from treatment with TroVax®

Strategic decision to close the US Phase II HRPC trial and focus on collaborative Phase II studies

The International Society for the Study of Xenobiotics in October 2012

FINANCIAL REVIEWThe Company’s net cash1 balance at 30 June 2012, as stated in the interim report, was £6.6 million (unaudited). The cash position has since been strengthened by £10.1 million net proceeds from a fundraising which completed in July 2012, in addition to a total £1.9 million option exercise payment from Sanofi for StarGen™ and UshStat®. At 31 October 2012, the Company had a net cash1 balance of £14.4 million (unaudited).

1. Cash, cash equivalents and available for sale investments

OUTLOOKOxford BioMedica remains focused on delivering the objectives set across its core ophthalmology portfolio, further developing its manufacturing capabilities and securing new industry alliances for its high-value products and intellectual property.

John Dawson, Chief Executive Officer of Oxford BioMedica, said: “The commercial prospects for our pioneering technologies continue to improve. Our priority remains to secure a strong future for the Company and, as we continue to deliver operational progress, we are increasingly well-placed to build a financially self-sustaining business via organic growth, new alliances and strategic corporate activity.”

-Ends-

Notes to editors

About Oxford BioMedica®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.